Novel Injection Methods (CPB 0777, reviewed 2026-10-27)
Aetna's CPB 0777 (reviewed 2026-10-27) clarifies coverage for novel injection methods in ophthalmology. Triamcinolone acetonide (Xipere) via suprachoroidal injection is covered for macular edema associated with uveitis when CPB 1000 criteria are met; all other suprachoroidal agents are experimental/unproven and not covered. Subretinal rtPA injection for sub-macular hemorrhage is covered when criteria are met. The Mercator Bullfrog micro-infusion device remains experimental/unproven and not covered.